Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center

Hayriye Sahinli; Esra Zeynelgil; Ozlem Dogan; Dogan Yazilitas

doi:doi:10.11648/j.jctr.20231101.11

| Peer-Reviewed

Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center

Hayriye Sahinli, Esra Zeynelgil, Ozlem Dogan, Dogan Yazilitas

Published in Journal of Cancer Treatment and Research (Volume 11, Issue 1)

Received: 25 February 2023 Accepted: 15 March 2023 Published: 31 March 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results: Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.

Published in	Journal of Cancer Treatment and Research (Volume 11, Issue 1)
DOI	10.11648/j.jctr.20231101.11
Page(s)	1-8
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Renal Cell Cancer, Tyrosine Kinase Inhibitor, Pazopanib, Sunitinib, First-Line Treatment

References

[1]	Ustuner M, Yaprak B, Teke K, et al. Coexisting papillary and clear renal cell carcinoma in the same kidney. Case Rep Urol. 2014; 2014: 575181.
[2]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71 (1): 7-33.
[3]	Capitanio U, Montorsi F. Renal cancer. Lancet. 2016; 387 (10021): 894-906.
[4]	Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, et al. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017; 60: 77-89.
[5]	Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005; 23 (4): 832-41.
[6]	Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20 (1): 289-96.
[7]	Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356 (22): 2271-81.
[8]	Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998; 338 (18): 1272-8.
[9]	Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007; 13 (4): 1098-106.
[10]	Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 115-24.
[11]	Sternberg CN. Pazopanib in renal cell carcinoma. Clin Adv Hematol Oncol. 2010; 8 (4): 232-3.
[12]	Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27 (22): 3584-90.
[13]	Lee JL, Park I, Park K, et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol. 2012; 138 (4): 687-93.
[14]	Staehler M, Panic A, Goebell PJ, et al. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. Int J Cancer. 2021; 148 (4): 950-60.
[15]	Kim JH, Park I, Lee JL. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol. 2016; 78 (2): 325-32.
[16]	Motzer RJ, McCann L, Deen K. Pazopanib versus sunitinib in renal cancer. N Engl J Med. 2013; 369 (20): 1970.
[17]	Lalani AA, Li H, Heng DYC, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Can Urol Assoc J. 2017; 11 (3-4): 112-7.
[18]	Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116 (18): 4256-65.
[19]	Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373 (9669): 1119-32.

Cite This Article

Plain Text BibTeX RIS

APA Style

Hayriye Sahinli, Esra Zeynelgil, Ozlem Dogan, Dogan Yazilitas. (2023). Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. Journal of Cancer Treatment and Research, 11(1), 1-8. https://doi.org/10.11648/j.jctr.20231101.11

Copy | Download

ACS Style

Hayriye Sahinli; Esra Zeynelgil; Ozlem Dogan; Dogan Yazilitas. Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. J. Cancer Treat. Res. 2023, 11(1), 1-8. doi: 10.11648/j.jctr.20231101.11

Copy | Download

AMA Style

Hayriye Sahinli, Esra Zeynelgil, Ozlem Dogan, Dogan Yazilitas. Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. J Cancer Treat Res. 2023;11(1):1-8. doi: 10.11648/j.jctr.20231101.11

Copy | Download

@article{10.11648/j.jctr.20231101.11,
  author = {Hayriye Sahinli and Esra Zeynelgil and Ozlem Dogan and Dogan Yazilitas},
  title = {Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center},
  journal = {Journal of Cancer Treatment and Research},
  volume = {11},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.jctr.20231101.11},
  url = {https://doi.org/10.11648/j.jctr.20231101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20231101.11},
  abstract = {Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results: Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.},
 year = {2023}
}

Copy | Download

TY - JOUR
T1 - Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center
AU - Hayriye Sahinli
AU - Esra Zeynelgil
AU - Ozlem Dogan
AU - Dogan Yazilitas
Y1 - 2023/03/31
PY - 2023
N1 - https://doi.org/10.11648/j.jctr.20231101.11
DO - 10.11648/j.jctr.20231101.11
T2 - Journal of Cancer Treatment and Research
JF - Journal of Cancer Treatment and Research
JO - Journal of Cancer Treatment and Research
SP - 1
EP - 8
PB - Science Publishing Group
SN - 2376-7790
UR - https://doi.org/10.11648/j.jctr.20231101.11
AB - Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results: Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.
VL - 11
IS - 1
ER -

Copy | Download

Author Information

Hayriye Sahinli

Ankara D?skap? Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey
Esra Zeynelgil

Ankara D?skap? Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey
Ozlem Dogan

Ankara D?skap? Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey
Dogan Yazilitas

Ankara D?skap? Yildirim Beyazit Training and Research Hospital, Medical Oncology Clinic, Ankara, Turkey

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Hayriye Sahinli, Esra Zeynelgil, Ozlem Dogan, Dogan Yazilitas. (2023). Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. Journal of Cancer Treatment and Research, 11(1), 1-8. https://doi.org/10.11648/j.jctr.20231101.11

Copy | Download

ACS Style

Hayriye Sahinli; Esra Zeynelgil; Ozlem Dogan; Dogan Yazilitas. Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. J. Cancer Treat. Res. 2023, 11(1), 1-8. doi: 10.11648/j.jctr.20231101.11

Copy | Download

AMA Style

Hayriye Sahinli, Esra Zeynelgil, Ozlem Dogan, Dogan Yazilitas. Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center. J Cancer Treat Res. 2023;11(1):1-8. doi: 10.11648/j.jctr.20231101.11

Copy | Download

@article{10.11648/j.jctr.20231101.11,
  author = {Hayriye Sahinli and Esra Zeynelgil and Ozlem Dogan and Dogan Yazilitas},
  title = {Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center},
  journal = {Journal of Cancer Treatment and Research},
  volume = {11},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.jctr.20231101.11},
  url = {https://doi.org/10.11648/j.jctr.20231101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20231101.11},
  abstract = {Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results: Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.},
 year = {2023}
}

Copy | Download